<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39552716</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-5370</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>EClinicalMedicine</Title><ISOAbbreviation>EClinicalMedicine</ISOAbbreviation></Journal><ArticleTitle>Incidence of post-acute COVID-19 symptoms across healthcare settings in seven countries: an international retrospective cohort study using routinely-collected data.</ArticleTitle><Pagination><StartPage>102903</StartPage><MedlinePgn>102903</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">102903</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eclinm.2024.102903</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The World Health Organisation (WHO) has identified a range of symptomatic manifestations to aid in the clinical diagnosis of post-COVID conditions, herein referred to as post-acute COVID-19 symptoms. We conducted an international network cohort study to estimate the burden of these symptoms in North American, European, and Asian populations.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A federated analysis was conducted including 10 databases from the United Kingdom, Netherlands, Norway, Estonia, Spain, France, South Korea, and the United States, between September 1st 2020 and latest data availability (which varied from December 31st 2021 to February 28th 2023), covering primary and secondary care, nationwide registries, and claims data, all mapped to the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM). We defined two cohorts for the main analyses: a SARS-CoV-2 infection cohort [positive polymerase chain reaction (PCR) or rapid lateral flow test (LFT) result or clinical COVID-19 diagnosis] and a general population cohort. Individuals with less than 365 days of prior history or 120 days of follow-up were excluded. We estimated incidence rates (IRs) of the 25 WHO-proposed post-acute COVID-19 symptoms, considering symptoms that occurred ≥90 and ≤365 days after index date, excluding individuals with the respective symptoms 180 days prior to the index event. Stratified analyses were conducted by age and sex. Incidence rate ratios (IRRs) were calculated comparing rates in the infected cohort versus the general population. Results from the different databases were combined using random-effects meta-analyses.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">3,019,408 individuals were included in the infection cohort. 1,585,160 of them were female and 1,434,248 of them male. 929,351,505 individuals were included in the general population group. 461,195,036 of them were female and 466,022,004 of them male. The 1-year IR of any post-acute COVID-19 symptom in the COVID-19 infection cohort varied significantly across databases, from 4.4 (95% CI 3.8-5.1) per 100 person-years to 103.9 (95% CI 103.2-104.7). The five most common symptoms were joint pain (from 1.6 (95% CI 1.3-1.9) to 14.3 (95% CI 14.1-14.6)), abdominal pain (from 0.3 (95% CI 0.1-0.5) to 9.9 (95% CI 9.7-10.1)), gastrointestinal issues (from 0.6 (95% CI 0.4-0.9) to 13.3 (95% CI 13.1-13.6)), cough (from 0.3 (95% CI 0.2-0.5) to 9.1 (95% CI 8.9-9.3)), and anxiety (from 0.8 (95% CI 0.6-1.2) to 11.4 (95% CI 11.2-11.6)); whereas muscle spasms (from 0.01 (95% CI 0.008-0.2) to 1.7 (95% CI 1.6-1.8)), pins and needles (from 0.05 (95% CI 0.03-0.0.9) to 1.5 (95% CI 1.4-1.6)), memory issues (from 0.03 (95% CI 0.02-0.06) to 0.8 (95% CI 0.7-0.8)), cognitive dysfunction (from 0.007 (95% CI 0.004-0.01) to 0.6 (95% CI 0.4-0.8)), and altered smell and/or taste (from 0.04 (95% CI 0.03-0.04) to 0.7 (95% CI 0.6-0.8)) were least common. Incidence rates of any post-acute COVID-19 symptoms generally increased with age, with certain symptoms peaking in middle-aged adults (anxiety, depressive disorders, headache, altered smell and taste) and others in pre-school children (gastrointestinal issues and cough). Females had higher incidence rates for most symptoms. Based on the random-effects model, the infected cohort had a higher incidence of any post-acute COVID-19 symptom than the general population, with a meta-analytic incidence rate ratio (meta-IRR) of 1.4 (1-2). A similar pattern was seen for all individual symptoms. The highest meta-IRRs were depressive disorder, 2.6 (1.7-3.9); anxiety, 2.3 (1.4-3.8); allergy, 2.1 (1.7-2.8) and sleep disorders, 2.1 (1.5-2.6). The meta-IRR for altered smell and/or taste was 1.9 (1.3-2.8).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="UNASSIGNED">Post-acute COVID-19 symptoms, as listed by the WHO, were commonly observed following COVID-19 infection. However, even after standardising research methods, there was significant heterogeneity in the incidence rates from different healthcare settings and geographical locations. This is the first international study of the epidemiology of post-acute COVID-19 symptoms using the WHO-listed symptoms. Its findings contibute to understand the epidemiology of this condition from a multinational approach. Limitations of this study include the lack of consensus of the post-acute COVID-19 definition, as well as the difficulty to capture the impact on daily life of the post-acute COVID-19 symptoms in the available datasets.</AbstractText><AbstractText Label="FUNDING" NlmCategory="UNASSIGNED">This work has been funded by the European Health Data Evidence Network (EHDEN) through an Evidence Generation Fund Grant and by the National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre (BRC).</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Junqing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>López-Güell</LastName><ForeName>Kim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dedman</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>CPRD, Medicines and Healthcare Products Regulatory Agency, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolde</LastName><ForeName>Raivo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>López-Blasco</LastName><ForeName>Raúl</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Biocomputing Unit, Aragon Health Sciences Institute (IACS), Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martínez</LastName><ForeName>Álvaro</ForeName><Initials>Á</Initials><AffiliationInfo><Affiliation>The Health Research Institute Hospital La Fe, Avenida Fernando Abril Martorell, 106 Torre A 7a Planta, 46026, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercier</LastName><ForeName>Gregoire</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Public Health Department, University Hospital of Montpellier, 34295 Montpellier, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IDESP, Université de Montpellier, INSERM, 34000, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abellan</LastName><ForeName>Alicia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arinze</LastName><ForeName>Johnmary T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuccu</LastName><ForeName>Zara</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>CPRD, Medicines and Healthcare Products Regulatory Agency, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmestri</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delseny</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Public Health Department, University Hospital of Montpellier, 34295 Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khalid</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Chungsoo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ji-Woo</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Big Data Department, Health Insurance Review and Assessment Service, Wonju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The OHDSI Center at the Roux Institute, Northeastern University, Portland, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loste</LastName><ForeName>Cora</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>REICOP (Red de Investigación Covid Persistente), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundació Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat de Vic - UCC, Vic, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mateu</LastName><ForeName>Lourdes</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Autònoma de Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>REICOP (Red de Investigación Covid Persistente), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundació Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat de Vic - UCC, Vic, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>Miguel A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Parc de Salut Mar, Hospital del Mar Medical Research Institute, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meléndez-Cardiel</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biocomputing Unit, Aragon Health Sciences Institute (IACS), Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercadé-Besora</LastName><ForeName>Núria</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosseveld</LastName><ForeName>Mees</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishimura</LastName><ForeName>Akihito</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordeng</LastName><ForeName>Hedvig M E</ForeName><Initials>HME</Initials><AffiliationInfo><Affiliation>Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Child Health and Development, Norwegian Institute of Public Health, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oyinlola</LastName><ForeName>Jessie O</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>CPRD, Medicines and Healthcare Products Regulatory Agency, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pérez-Crespo</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pineda-Moncusí</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramírez-Anguita</LastName><ForeName>Juan Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Parc de Salut Mar, Hospital del Mar Medical Research Institute, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trinh</LastName><ForeName>Nhung T H</ForeName><Initials>NTH</Initials><AffiliationInfo><Affiliation>Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uusküla</LastName><ForeName>Anneli</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valdivieso</LastName><ForeName>Bernardo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Health Research Institute Hospital La Fe, Avenida Fernando Abril Martorell, 106 Torre A 7a Planta, 46026, Valencia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The University and Polytechnic La Fe Hospital of Valencia, Avenida Fernando Abril Martorell, 106 Torre H 1a Planta, 46026, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burkard</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Català</LastName><ForeName>Martí</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paredes</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Global Health and Diseases, Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Infectious Diseases (CIBERINFEC), Institute of Health Carlos III (ISCIII), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat Autònoma de Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundació Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universitat de Vic - UCC, Vic, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jödicke</LastName><ForeName>Annika M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>EClinicalMedicine</MedlineTA><NlmUniqueID>101733727</NlmUniqueID><ISSNLinking>2589-5370</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Incidence of post-acute COVID-19 symptoms</Keyword><Keyword MajorTopicYN="N">International cohort study</Keyword><Keyword MajorTopicYN="N">Post-acute COVID-19 condition</Keyword><Keyword MajorTopicYN="N">Real world data</Keyword></KeywordList><CoiStatement>D.P.A.‘s department has received grant/s from Amgen, Chiesi–Taylor, Lilly, Janssen, Novartis, and UCB Biopharma. His research group has received consultancy fees from Astra Zeneca and UCB Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners and UCB Biopharma have funded or supported training programmes organised by DPA's department. R.P. reports serving on advisory boards for Gilead Sciences, Inc, Pfizer, Inc, Roche Therapeutics, MSD, GSK, ViiV Healthcare, Eli Lilly and Company, PharmaMar, and Atea Pharmaceuticals, Inc; and receiving research grants paid to his institution from MSD, ViiV Healthcare, Gilead Sciences, and PharmaMar. L.M. reports receiving grants from Grifols; receiving honoraria as a speaker from AstraZeneca, Gilead Sciences, GSK, and Pfizer; and participation in advisory boards for Gilead Sciences and Merck. M.M. works for a research group that in the past 3 years received unconditional research grants from Chiesi, UCB, Amgen, Johnson &amp; Johnson, Innovative Medicines Initiative and the European Medicines Agency. D.Ded., Z.C. and J.O. are employees of the Medicines and Healthcare Products Regulatory Agency, which provides the CPRD research service. K.K. is a consortial author in the US National Institutes of Health National COVID Cohort Collaborative (funding expired in 2022 with no renewal or active impact on any current work). G.M. reports receiving consulting fees from Pfizer. A.N. reports grants or contracts from Alfred P. Sloan Foundation, National Institutes of Health and the U.S. Food and Drug Administration. L.P. was supported by a Sara Borrell fellowship awarded by the Spanish Institute of Health Carlos III (CD23/00223). K.L.G is funded through an MRC scholarship with Bayer AG as an industrial partner. All other co-authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>11</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>5</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39552716</ArticleId><ArticleId IdType="pmc">PMC11564986</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2024.102903</ArticleId><ArticleId IdType="pii">S2589-5370(24)00482-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nalbandian A., Desai A.D., Wan E.Y. Post-COVID-19 condition. Annu Rev Med. 2023;74:55–64.</Citation><ArticleIdList><ArticleId IdType="pubmed">35914765</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long covid—mechanisms, risk factors, and management. BMJ. 2021;374:n1648.</Citation><ArticleIdList><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodgson C.L., Broadley T. Long COVID—unravelling a complex condition. Lancet Respir Med. 2023;11:667–668.</Citation><ArticleIdList><ArticleId IdType="pubmed">37475126</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 rapid guideline: managing the long-term effects of COVID-19. National Institute for Health and Care Excellence (NICE); London: 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">33555768</ArticleId></ArticleIdList></Reference><Reference><Citation>Carcaillon-Bentata L., Makovski T.T., Alleaume C., et al. Post-Covid-19 condition: a comprehensive analysis of the World Health Organisation definition. J Infect. 2023;87:e83–e87.</Citation><ArticleIdList><ArticleId IdType="pubmed">37604211</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102–e107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi O.L., Hughes S.E., Turner G., et al. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021;114:428–442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8450986</ArticleId><ArticleId IdType="pubmed">34265229</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Haupert S.R., Zimmermann L., Shi X., Fritsche L.G., Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022;226:1593–1607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Horberg M.A., Watson E., Bhatia M., et al. Post-acute sequelae of SARS-CoV-2 with clinical condition definitions and comparison in a matched cohort. Nat Commun. 2022;13:5822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9556630</ArticleId><ArticleId IdType="pubmed">36224218</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Nirantharakumar K., Hughes S., et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28:1706–1714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballouz T., Menges D., Anagnostopoulos A., et al. Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study. BMJ. 2023;381</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10230608</ArticleId><ArticleId IdType="pubmed">37257891</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter R.S., Nieters A., Kräusslich H.G., et al. Post-acute sequelae of covid-19 six to 12 months after infection: population based study. BMJ. 2022;379</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9557001</ArticleId><ArticleId IdType="pubmed">36229057</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering A.V., van Zon S.K.R., Olds Hartman T.C., Rosmalen J.G.M. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400:452–461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E., Altman D.G., Egger M., et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806–808. doi: 10.1136/bmj.39335.541782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39335.541782</ArticleId><ArticleId IdType="pmc">PMC2034723</ArticleId><ArticleId IdType="pubmed">17947786</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrett E., Gallagher A.M., Bhaskaran K., et al. Data resource profile: clinical practice research Datalink (CPRD) Int J Epidemiol. 2015;44:827–836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4521131</ArticleId><ArticleId IdType="pubmed">26050254</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf A., Dedman D., Campbell J., et al. Data resource profile: clinical practice research Datalink (CPRD) Aurum. Int J Epidemiol. 2019;48:1740. 1740g.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6929522</ArticleId><ArticleId IdType="pubmed">30859197</ArticleId></ArticleIdList></Reference><Reference><Citation>Data resource profile: the integrated primary care information (IPCI) database, the Netherlands - PubMed. https://pubmed.ncbi.nlm.nih.gov/35182144/</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9749682</ArticleId><ArticleId IdType="pubmed">35182144</ArticleId></ArticleIdList></Reference><Reference><Citation>Recalde M., Rodríguez C., Burn E., et al. Data resource profile: the information system for research in primary care (SIDIAP) Int J Epidemiol. 2022;51:e324–e336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9749711</ArticleId><ArticleId IdType="pubmed">35415748</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer M.A., Furlong L.I., Torre P., et al. Reuse of EHRs to support clinical research in a hospital of reference. Stud Health Technol Inform. 2015;210:224–226.</Citation><ArticleIdList><ArticleId IdType="pubmed">25991136</ArticleId></ArticleIdList></Reference><Reference><Citation>Montpellier, C. H. U. de Entrepôt de Données de Santé, eDOL. CHU de Montpellier: Site Internet. https://www.chu-montpellier.fr/fr/plateformes-recherche/eds</Citation></Reference><Reference><Citation>IQVIA PharMetrics® Plus. https://www.iqvia.com/locations/united-states/library/fact-sheets/iqvia-pharmetrics-plus</Citation></Reference><Reference><Citation>Transforming Estonian health data to the observational medical outcomes partnership (OMOP) common data model: lessons learned - PubMed. https://pubmed.ncbi.nlm.nih.gov/38058679/</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10697784</ArticleId><ArticleId IdType="pubmed">38058679</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakken I.J., Ariansen A.M.S., Knudsen G.P., Johansen K.I., Vollset S.E. The Norwegian patient registry and the Norwegian registry for primary health care: research potential of two nationwide health-care registries. Scand J Public Health. 2020;48:49–55.</Citation><ArticleIdList><ArticleId IdType="pubmed">31288711</ArticleId></ArticleIdList></Reference><Reference><Citation>Data standardization – OHDSI. https://www.ohdsi.org/data-standardization/</Citation></Reference><Reference><Citation>Balduzzi S., Rücker G., Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. BMJ Ment Health. 2019;22:153–160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10231495</ArticleId><ArticleId IdType="pubmed">31563865</ArticleId></ArticleIdList></Reference><Reference><Citation>Raventós B., Català M., Du M., et al. IncidencePrevalence: an R package to calculate population-level incidence rates and prevalence using the OMOP common data model. Pharmacoepidemiol Drug Saf. 2024;33</Citation><ArticleIdList><ArticleId IdType="pubmed">37876360</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Mahoney L.L., Routen A., Gillies C., et al. The prevalence and long-term health effects of long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. eClinicalMedicine. 2023;55:101762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker A.J., MacKenna B., Inglesby P., et al. Clinical coding of long COVID in English primary care: a federated analysis of 58 million patient records in situ using OpenSAFELY. Br J Gen Pract. 2021;71:e806–e814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8340730</ArticleId><ArticleId IdType="pubmed">34340970</ArticleId></ArticleIdList></Reference><Reference><Citation>Maisel P., Baum E., Donner-Banzhoff N. Fatigue as the chief complaint. Dtsch Ärztebl Int. 2021;118:566–576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8579431</ArticleId><ArticleId IdType="pubmed">34196270</ArticleId></ArticleIdList></Reference><Reference><Citation>McCabe M., Patricia B. Fatigue in the acute care and ambulatory setting. J Pediatr Nurs. 2014;29:344–347.</Citation><ArticleIdList><ArticleId IdType="pubmed">24650424</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson E.J., Williams D.M., Walker A.J., et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. 2022;13:3528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelà G., Goldoni M., Solinas E., et al. Sex-related differences in long-COVID-19 syndrome. J Womens Health. 2002;31:620–630.</Citation><ArticleIdList><ArticleId IdType="pubmed">35333613</ArticleId></ArticleIdList></Reference><Reference><Citation>Kostka K., et al. “The burden of post-acute COVID-19 symptoms in a multinational network cohort analysis”. Nat Commun. 2023;14:7449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10656441</ArticleId><ArticleId IdType="pubmed">37978296</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson T., Pinto Pereira S.M., Nugawela M.D., et al. Long COVID-six months of prospective follow-up of changes in symptom profiles of non-hospitalised children and young people after SARS-CoV-2 testing: a national matched cohort study (The CLoCk) study. PLoS One. 2023;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9987792</ArticleId><ArticleId IdType="pubmed">36877677</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>